Innovation in Anti-Malaria

Market model that paid enough to cover R&D in production costs is needed. We have tried in England in our NHS working with Nice and the Health Economics Unit in York, a pilot of two new antibiotics looking at value. The other area we need innovation is of course vaccines and the mRNA. I'm told could be used for bacteria. That would be great. And there will be bacteria that experts will feel we could get vaccines for. They've got the issue of can we persuade people to take them when they're in their own interest? So it can be done with innovation. Usually at the beginning it costs more, but most innovations with time and practise come down in price.